🇺🇸 FDA
Pipeline program

DTX401

401GSDIA01

Phase 2 gene_therapy completed

Quick answer

DTX401 for GSD1 is a Phase 2 program (gene_therapy) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
GSD1
Phase
Phase 2
Modality
gene_therapy
Status
completed

Clinical trials